Lovelace Biomedical Research Institute
UEI MBT9RXJJ7428 · NM · SAM.gov record ↗
$18.9M
FY2025 obligations
30
Contract awards
Dec 19, 2018
First action
Sep 30, 2025
Latest action
Obligations by agency
- Department Of Health And Human Services$18.9M
- Department Of Defense$42K
Obligations by NAICS
Monthly obligations
Oct 24
Nov 24
Dec 24
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Contracts ending within 18 months (recompete watch)
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75A50123F61001 ↗ | BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES | Office Of Assistant Secretary For Preparedness And Response | 541714 | $21K | Jul 20, 2023 | Jul 19, 2026 |
| 75A50123F61001 ↗ | RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]) | Office Of Assistant Secretary For Preparedness And Response | 541714 | $2.0M | Sep 29, 2023 | Sep 18, 2026 |
| 75F40122F19001 ↗ | INCREASE CLINICAL STUDY TIME | Food And Drug Administration | 541690 | $0 | Sep 22, 2022 | Sep 22, 2026 |
| 75F40123F19002 ↗ | TASK ORDER 2 - EXAMINING THE INFLUENCE OF SYNTHETIC COOLING AGENTS ON CIGARETTE SENSORY AND SUBJECTIVE EFFECTS AND USE BEHAVIOR | Food And Drug Administration | 541690 | $0 | Sep 29, 2023 | Sep 29, 2026 |
| 75F40125P00216 ↗ | SOLE SOURCE AWARD OF A 24-MONTH PERIOD, FIRM FIXED PRICE (FFP), ENDS TOXICOLOGICAL STUDIES FOR CENTER FOR TOBACCO PRODUCTS (CTP). | Food And Drug Administration | 541380 | $7.1M | Sep 19, 2025 | Sep 29, 2027 |
Largest awards
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75F40119C10161 ↗ | STUDY OF E-CIGARETTE AEROSOL TOXICITY IN IN VIVO NONCLINICAL MODELS. | Food And Drug Administration | 541380 | $9.8M | Sep 26, 2019 | Jun 30, 2025 |
| 75F40125P00216 ↗ | SOLE SOURCE AWARD OF A 24-MONTH PERIOD, FIRM FIXED PRICE (FFP), ENDS TOXICOLOGICAL STUDIES FOR CENTER FOR TOBACCO PRODUCTS (CTP). | Food And Drug Administration | 541380 | $7.1M | Sep 19, 2025 | Sep 29, 2027 |
| 75A50123F61001 ↗ | RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]) | Office Of Assistant Secretary For Preparedness And Response | 541714 | $2.0M | Sep 29, 2023 | Sep 18, 2026 |
| 75N95020F00001 ↗ | NON-CLINICAL SAFETY ASSESSMENT OF GENE THERAPY (PCCA, MMAB, DOK7 AND COLQ) TO SUPPORT PLATFORM GENE THERAPY FOR CONGENITAL MYASTHENIC DISEASES (DOK7, COLQ) AND ACIDEMIA (PCCA, MMAB) | National Institutes Of Health | 541712 | $1.7M | Sep 25, 2020 | May 24, 2026 |
| 75N93022F00001 ↗ | TRANSFER, VALIDATION AND QUALIFICATION OF BIOANALYTICAL METHODS FOR DETECTION OF CABOTEGRAVIR AND LEVONORGESTREL IN RAT AND NONHUMAN PRIMATE PLASMA | National Institutes Of Health | 541715 | $139K | Nov 15, 2021 | Nov 14, 2025 |
| W81XWH22P0157 ↗ | ANNUAL SOFTWARE LICENSE/MAINTENANCE AGREEMENT FOR THE ANIMAL MANAGEMENT SYSTEM. | Defense Health Agency | 511210 | $42K | Sep 16, 2022 | Sep 19, 2025 |
| 75A50123F61001 ↗ | BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES | Office Of Assistant Secretary For Preparedness And Response | 541714 | $21K | Jul 20, 2023 | Jul 19, 2026 |
| 75N93025D00021 ↗ | EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES. | National Institutes Of Health | 541715 | $10K | Sep 30, 2025 | — |
| 75N93022D00009 ↗ | THE CONTRACTOR SHALL PROVIDE PRECLINICAL DEVELOPMENT SUPPORT FOR CANDIDATE PRODUCTS AND DRUG DEVELOPMENT ACTIVITIES. | National Institutes Of Health | 541715 | $0 | Nov 15, 2021 | — |
| 75F40122F19001 ↗ | INCREASE CLINICAL STUDY TIME | Food And Drug Administration | 541690 | $0 | Sep 22, 2022 | Sep 22, 2026 |
| 75N95022F00001 ↗ | BIOANALYTICAL SUPPORTS FOR A GLP TOX/BIODISTRIBUTION STUDY IN MINI-PIGS | National Institutes Of Health | 541715 | $0 | Jun 17, 2022 | Jun 30, 2025 |
| 75N95020F00005 ↗ | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. | National Institutes Of Health | 541715 | $0 | Sep 25, 2020 | Jul 15, 2025 |
| 75A50122D00008 ↗ | LOVELACE BIOMEDICAL RESEARCH INSTITUTE(CHEM) - IDIQ FOR BARDA CRN ANIMAL MODEL DEVELOPMENT | Office Of Assistant Secretary For Preparedness And Response | 541714 | $0 | Jul 28, 2022 | — |
| 75N95020F00003 ↗ | NATURAL HISTORY STUDIES IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS. | National Institutes Of Health | 541715 | $0 | Sep 28, 2020 | Jul 31, 2025 |
| 75F40123F19001 ↗ | TASK ORDER 1 -TITLE: ARE REDUCTIONS IN BOE, BOPH, AND OTHER HEALTH RISK MARKERS PROPORTIONAL TO REDUCTIONS IN CIGARETTE SMOKING UPON SWITCHING TO ENDS | Food And Drug Administration | 541690 | $0 | Sep 27, 2023 | Mar 29, 2026 |
| 75F40123F19002 ↗ | TASK ORDER 2 - EXAMINING THE INFLUENCE OF SYNTHETIC COOLING AGENTS ON CIGARETTE SENSORY AND SUBJECTIVE EFFECTS AND USE BEHAVIOR | Food And Drug Administration | 541690 | $0 | Sep 29, 2023 | Sep 29, 2026 |
| 75N95020F00002 ↗ | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN. | National Institutes Of Health | 541715 | $0 | Sep 18, 2020 | Jun 30, 2025 |
| HT001122D0030 ↗ | OMNIBUS IV MILITARY MEDICAL RESEARCH AND DEVELOPMENT. | Defense Health Agency | 541714 | $0 | Jun 20, 2022 | — |
| 75N95024F00001 ↗ | EVALUATION OF POTENTIAL RESPIRATORY STIMULANT. TO4. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MAY 30, 2025. | National Institutes Of Health | 541715 | $0 | Mar 21, 2024 | May 30, 2025 |
| 75N95019D00030 ↗ | EOI::IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI NOTICE OF TERMINATION FOR CONVENIENCE CRO SUPPORT FOR NCATS MEDICINAL CHEMISTRY FOR LEAD OPTIMIZATION. | National Institutes Of Health | 541715 | $0 | Sep 26, 2019 | — |
| 75N95021F00001 ↗ | CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN | National Institutes Of Health | 541715 | $0 | Sep 24, 2021 | Mar 31, 2026 |
| 75N95024F00002 ↗ | RESPIRATORY INTERACTION STUDIES IN RODENTS, ABILITY OF A TEST ARTICLE TO REVERSE THE RESPIRATORY DEPRESSANT EFFECTS OF OPIOIDS. TO5.POP: MARCH 21, 2024 - MARCH 31, 2026. | National Institutes Of Health | 541715 | $0 | Mar 21, 2024 | Mar 31, 2026 |
| 75N92021F00001 ↗ | GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY/TOXICOLOGY CORE LABORATORY - SCIENTIFIC PROJECT FOR RSA NO. 2057 (RADER) | National Institutes Of Health | 541714 | $-29K | Sep 8, 2021 | Jun 30, 2024 |
| 75N93019F00131 ↗ | TRANSFER AND VALIDATION OF BIOANALYTICAL METHOD FOR DETECTION OF CABOTEGRAVIR IN RAT PLASMA | National Institutes Of Health | 541712 | $-56K | Aug 1, 2019 | Jul 31, 2022 |
| 75N95020F00004 ↗ | CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES. | National Institutes Of Health | 541715 | $-79K | Sep 22, 2020 | Dec 31, 2024 |